PCN64 - Cost-Utility Analysis of Eox Drug Regimen Versus Dcf Drug Regimen for the Patients with Advanced Gastric Cancer in Shiraz in 2015

Abstract

Tittle: Cost-Utility Analysis of EOX Drug Regimen versus DCF Drug Regimen for the Patients with Advanced gastric cancer in Shiraz in 2015 Authors: Khezeli MJ, dehghani M, keshavarz K, kavosi Z 1Student Research Committee, Department of Health Economics, School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, IR Iran 2Hematology and Oncology Ward, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran 3Health human Resources Research Center,School of Management & Information Science ,Shiraz University Of Medical Science ,Shiraz,Iran 4Health human Resources Research Center,School of Management & Information Science ,Shiraz University Of Medical Science ,Shiraz,Iran This study aimed to evaluate the cost- utility of using EOX versus DCF drug regimens in patients with advanced gastric cancer in southern Iran This cross-sectional study was an economic evaluation of cost- utility type that included all the patients who were using EOX or DCF treatments and had advanced gastric cancer. All costs and QALY were calculated, and finally, one-way sensitivity analysis was performed to ensure the results A total of 54 patients participated in this study, amongst whom 20 were using EOX drugs and 34 had a DCF regimen. The mean quality of life in the DCF and EOX groups was 0.747 and 0.836, respectively. The costs of the DCF treatment group (32053$) was higher than those of the EOX group (11177$). The results obtained from the costs and the utility showed that the EOX drug regimen was cost-effective due to lower costs and higher utility than DCF. The one-way sensitivity analysis also showed the accuracy of the results Due to the cost-effectiveness of the EOX drug regimen compared to DCF, it is recommended that oncology specialists use this medication to treat gastric cancer patients.